阿德福韦酯治疗低病毒载量乙型肝炎相关活动性肝硬化的疗效

Efficacy of Adefovir in treatment of low viral load of HBV related liver cirrhosis

目的观察乙肝肝硬化低病毒载量患者应用阿德福韦酯治疗的效果。方法阿德福韦酯10 mg,1次/d,口服,治疗乙肝肝硬化患者57例,疗程48周。观察治疗后肝功能ALT、ALB、透明质酸(HA)的变化,HBV DNA阴转率、HBeAg阴转率及血清转换率。结果治疗48周HBV DNA阴转率为68.4%,ALT复常率71.9%,HBeAg阴转率33.3%(14/42),HBeAg血清转换率16.7%(7/42),透明质酸较治疗前明显下降,差异具有统计学意义(P<0.01)。结论阿德福韦酯治疗低病毒载量乙型肝炎肝硬化患者取得较好的病毒学及生化学应答,不良反应轻微。

Objective To observe efficacy of Adefovir in treatment of low viral load of HBV related liver cirrhosis. Methods A defovir 10 mg （once a clay） was administrated in 57 patients with HBV related liver cirrhosis for 48 weeks. The changes of liver function ALT, ALB, HA and negative conversion rates of HBV DNA and HBeAg, and ser- um conversion rate were observed after treatment. Results After 48 weeks treatment, negative conversion rate of HBV DNA was 68.4% , recovery rate of ALT was 71.9% , negative conversion rate of HBeAg was 33.3% （14/42） , serum conversion rate of HBeAg was 16.7% （7/42） , hyaluronic acid obviously reduced compared with before treatment （P 〈 0.01 ）. Conclusion Adefovir in treatment of low viral load of HBV related liver cirrhosis has good reaction of virology and biochemistry. Adverse reaction is mild.